Astellas expands alliance with Seattle Genetics for antibody-drug conjugates
This article was originally published in Scrip
Executive Summary
The Astellas group company Agensys has paid $12 million to extend its collaboration with Seattle Genetics for the development of antibody-drug conjugates (ADCs). The deal could be worth up to $350 million in development and sales milestones to Seattle Genetics should all the new projects be successful.